NCT07360665

Brief Summary

People with psychotic disorders, such as schizophrenia, often experience significant difficulties in daily functioning, physical health, and quality of life. Long-acting injectable antipsychotics are an important part of treatment, but they can be associated with metabolic side effects and reduced physical fitness. Physical exercise has shown potential benefits for mental and physical health in this population; however, structured exercise programs implemented in real-world psychiatric services are still limited. The purpose of this study is to evaluate the feasibility and clinical impact of a structured, multimodal physical exercise program for adults with psychosis who are receiving long-acting injectable antipsychotic treatment. The study aims to determine whether participation in a supervised exercise program can improve physical functioning, psychological well-being, and selected biological markers related to brain health and metabolism. This study will be conducted in an outpatient psychiatric setting in Portugal and will include adults diagnosed with psychosis who are currently treated with long-acting injectable antipsychotics. Participants will be allocated to either an exercise group or a control group receiving usual care. The exercise program will last 24 weeks and will include aerobic, strength, mobility, and flexibility exercises, with supervised sessions conducted by qualified professionals. Participants will be assessed at baseline, during the intervention, after completion of the program, and at follow-up. Assessments will include measures of physical function, body composition, psychological well-being, quality of life, and blood-based biomarkers such as brain-derived neurotrophic factor, dopamine, serotonin, and metabolic indicators. The main hypothesis of this study is that individuals who participate in the physical exercise program will show improvements in physical function, mood, and overall well-being compared with those receiving usual care alone. The results of this study are expected to provide practical evidence to support the integration of structured physical exercise as an adjunct to routine psychiatric care for people with psychosis.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
7mo left

Started Jan 2026

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress38%
Jan 2026Nov 2026

First Submitted

Initial submission to the registry

December 17, 2025

Completed
15 days until next milestone

Study Start

First participant enrolled

January 1, 2026

Completed
21 days until next milestone

First Posted

Study publicly available on registry

January 22, 2026

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2026

Last Updated

April 29, 2026

Status Verified

January 1, 2026

Enrollment Period

10 months

First QC Date

December 17, 2025

Last Update Submit

April 28, 2026

Conditions

Outcome Measures

Primary Outcomes (14)

  • Body mass/weight

    Body mass/weight measured in kilograms using a calibrated scale.

    Baseline, 12 weeks, 24 weeks, 8-week post-intervention follow-up

  • Body mass index (BMI)

    BMI calculated as weight (kg) / height (m²)

    Baseline, 12 weeks, 24 weeks, 8-week post-intervention follow-up

  • Body fat percentage

    Body fat percentage assessed by electrical bioimpedance analysis

    Baseline, 12 weeks, 24 weeks, 8-week post-intervention follow-up

  • Lean body mass

    Lean body mass (kg) assessed by electrical bioimpedance analysis

    Baseline, 12 weeks, 24 weeks, 8-week post-intervention follow-up

  • Sit-to-Stand Test _ 30s

    Used to measure lower limb strength and endurance through the number of repetitions performed in a specific period.

    Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up

  • Handgrip Test

    Used to assess upper limb muscle strength

    Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up

  • European Health Interview Survey - Quality of Life 8-item Index (EUROHIS-QOL-8)

    The European Health Interview Survey - Quality of Life 8-item Index (EUROHIS-QOL-8) is an 8-item self-report questionnaire assessing overall quality of life across physical, psychological, social, and environmental domains. Each item is rated on a 5-point Likert scale, resulting in a total score ranging from 8 to 40. Higher total scores indicate better perceived quality of life. The scale demonstrates good psychometric properties and is suitable for use in clinical and research settings.

    Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up

  • Patient Health Questionnaire-9 - PHQ-9

    The Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-administered questionnaire designed to assess the severity of depressive symptoms based on the diagnostic criteria for major depressive episodes. Each item is scored on a 4-point Likert scale (0-3), yielding a total score ranging from 0 to 27. Higher total scores indicate greater severity of depressive symptoms. The PHQ-9 is widely used in clinical and research settings and demonstrates good psychometric properties.

    Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up

  • Positive and Negative Affect Scale (PANAS)

    The Positive and Negative Affect Schedule (PANAS) is a 20-item self-report questionnaire designed to assess affective states, comprising two independent 10-item subscales: Positive Affect (PANAS-PA) and Negative Affect (PANAS-NA). Each item is rated on a 5-point Likert scale (1-5), yielding subscale scores ranging from 10 to 50. Higher scores on the Positive Affect subscale indicate higher levels of positive affect, whereas higher scores on the Negative Affect subscale indicate higher levels of negative affect. The PANAS is widely used in clinical and research settings and demonstrates good psychometric properties.

    Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up

  • Serum Brain-Derived Neurotrophic Factor (BDNF) levels

    Serum BDNF concentration quantified using standardized Human BDNF ELISA Kit (Abcam). BDNF is a key neurotrophic marker associated with neuroplasticity and treatment-related neurobiological adaptations. Units: ng/mL.

    Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up

  • Serum lipid profile

    Assessment of serum lipid parameters including total cholesterol, HDL cholesterol, LDL cholesterol (direct or calculated), and triglycerides, according to hospital laboratory reference standards. Units: mg/dL. Hospital laboratory references: * Total cholesterol: \< 200 mg/dL * LDL cholesterol: \< 130 mg/dL * HDL cholesterol: \> 60 mg/dL * Triglycerides: \< 150 mg/dL

    Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up

  • Glycemic and metabolic markers

    Evaluation of fasting blood glucose and glycated hemoglobin (HbA1c) as indicators of glycemic control and metabolic health. Units: * Glucose: mg/dL * HbA1c: % Hospital reference values: * Glucose: 74-106 mg/dL * HbA1c: 4.0-6.0 %

    Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up

  • Serum Serotonin levels

    Quantification of serotonin concentration in serum using standardized laboratory procedures. Higher or lower concentrations will be interpreted as neurochemical modulation potentially associated with the exercise intervention and antipsychotic treatment. Unit: ng/mL

    Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up

  • Serum Dopamine levels

    Quantification of dopamine concentration in serum using standardized laboratory procedures. Changes in dopamine concentration across timepoints will be analyzed as a marker of neurochemical modulation potentially associated with the exercise intervention and antipsychotic treatment. Unit: ng/mL or pg/mL

    Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up

Secondary Outcomes (1)

  • Height

    Baseline

Other Outcomes (1)

  • Sociodemographic Characterization

    Baseline

Study Arms (2)

Patients diagnosed with psychosis who are receiving farmacological treatment and exercise program.

EXPERIMENTAL

Patients aged 18 years or older, diagnosed with psychosis, undergoing treatment with LAIs, and holding a certificate of autonomy issued by their psychiatrist, with the additional requirement for the experimental group to reside near the location of the physical exercise sessions.

Other: Physical Exercise

Patients diagnosed with psychosis who are receiving farmacological treatment.

NO INTERVENTION

Patients aged 18 years or older, diagnosed with psychosis, undergoing treatment with LAIs, and holding a certificate of autonomy issued by their psychiatrist.

Interventions

The program will be multimodal, integrating various exercise components. The aerobic component will consist of activities like walking, cycling, and circuit training. The functional strength component will include 2 to 3 exercises for the lower limbs, 2 to 3 exercises for the upper limbs, 1 to 2 exercises for the trunk and abdominal muscles, as well as 1 to 2 multi-joint exercises like burpees, swing kettlebell, among others. Lastly, the program will also incorporate mobility, balance, and flexibility exercises, such as stretching, postures, and joint mobilization.

Also known as: Multimodal Physical Exercise
Patients diagnosed with psychosis who are receiving farmacological treatment and exercise program.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 years or older;
  • Clinical diagnosis of psychosis;
  • Currently undergoing treatment with long-acting injectable antipsychotics (LAIs);
  • Follow-up at the Antipsychotic Clinic of ULSTMAD;
  • Certificate of autonomy issued by the treating psychiatrist, confirming the participant's capacity to engage in the study procedures;
  • Ability to provide written informed consent, either personally or through a legal representative;
  • (Experimental group only) Residence within a reasonable distance from the physical exercise intervention site to allow attendance at supervised sessions.

You may not qualify if:

  • Attendance below 85% of the supervised exercise sessions (experimental group);
  • Failure to complete the four main assessment time points;
  • Withdrawal or lack of informed consent at any stage of the study;
  • Not prescribed long-acting injectable antipsychotics (LAIs);
  • Not affiliated with or followed at the Antipsychotic Clinic of ULSTMAD.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Local Health Unit of Trás-os-Montes and Alto Douro

Vila Real, 5000, Portugal

RECRUITING

MeSH Terms

Conditions

Psychotic DisordersMental Disorders

Interventions

Exercise

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 17, 2025

First Posted

January 22, 2026

Study Start

January 1, 2026

Primary Completion (Estimated)

October 31, 2026

Study Completion (Estimated)

November 30, 2026

Last Updated

April 29, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Individual participant data (IPD) will not be shared. The dataset includes sensitive clinical, functional, and health-related information collected in a hospital setting. Data will be used exclusively for the purposes defined in the approved study protocol and in accordance with institutional ethical approval and data protection regulations.

Locations